BOOK
Eosinophil-Associated Disorders, An Issue of Immunology and Allergy Clinics of North America, E-Book
(2015)
Additional Information
Book Details
Abstract
This issue of Immunology and Allergy Clinics of North America, Guest Edited by Amy D. Klion, MD and Princess U. Ogbogu, MD, is devoted to Eosinophil-Associated Disorders. Drs. Klion and Ogbogu have assembled a group of expert authors to review the following topics: Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia; Spectrum of Eosinophilic End Organ Manifestations; Eosinophilia in GI disorders; Eosinophilia in Hematologic Disorders; Eosinophilia in Rheumatologic/Vascular Disorders; Eosinophilia in Pulmonary Disorders; Eosinophilia in Infectious Diseases; Eosinophilia associated with Immune Deficiency and Immune Dysregulation; Eosinophilia in Dermatologic disorders; Management of Hypereosinophilic Syndromes; and Novel Therapies for Eosinophilic Disorders.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Eosinophil-Associated Disorders\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | vii | ||
| Immunology And Allergy Clinics Of North America\r | x | ||
| Preface | xi | ||
| Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia | 387 | ||
| Key points | 387 | ||
| Eosinophil biology | 387 | ||
| Eosinophilia | 388 | ||
| Causes of hypereosinophilia | 389 | ||
| Drug Hypersensitivity | 389 | ||
| Allergic Disorders | 390 | ||
| Infection | 390 | ||
| Neoplasm | 391 | ||
| Other | 392 | ||
| Hypereosinophilic Syndrome | 393 | ||
| Lymphocytic Hypereosinophilic Syndrome | 395 | ||
| Myeloproliferative Hypereosinophilic Syndrome | 395 | ||
| Other Categories of Hypereosinophilic Syndrome | 396 | ||
| Approach to the Evaluation of Patients with Persistent, Marked Eosinophilia | 397 | ||
| Summary | 399 | ||
| References | 399 | ||
| Spectrum of Eosinophilic End-Organ Manifestations | 403 | ||
| Key points | 403 | ||
| Introduction | 403 | ||
| Mechanisms of end-organ manifestations | 404 | ||
| Gastrointestinal | 405 | ||
| Pulmonary | 405 | ||
| Upper airway and sinuses | 406 | ||
| Cardiovascular | 406 | ||
| Neurologic | 407 | ||
| Skin | 407 | ||
| Renal and genitourinary | 407 | ||
| Summary | 408 | ||
| References | 408 | ||
| Eosinophils in Gastrointestinal Disorders | 413 | ||
| Key points | 413 | ||
| Introduction | 414 | ||
| Eosinophilic gastrointestinal diseases | 414 | ||
| Eosinophilic Esophagitis | 414 | ||
| Epidemiology | 414 | ||
| Risk factors | 414 | ||
| Pathophysiology | 414 | ||
| Clinical features | 416 | ||
| Association with eosinophilia | 416 | ||
| Acute and chronic management | 416 | ||
| Overview | 416 | ||
| Acute | 417 | ||
| Chronic | 417 | ||
| Drugs | 417 | ||
| Systemic and topical corticosteroids | 417 | ||
| Proton pump inhibitors | 417 | ||
| Biologic agents | 418 | ||
| Diet | 418 | ||
| Elemental diet | 418 | ||
| Targeted diet | 418 | ||
| Six food group elimination diet | 418 | ||
| Dilation | 418 | ||
| Other considerations | 418 | ||
| Differential diagnosis | 418 | ||
| Prognosis | 419 | ||
| Eosinophilic gastritis, gastroenteritis, and colitis | 419 | ||
| Clinical features | 419 | ||
| Association with eosinophilia | 419 | ||
| Acute and chronic management | 420 | ||
| Differential diagnosis | 420 | ||
| Natural history | 420 | ||
| Celiac disease | 420 | ||
| Epidemiology | 420 | ||
| Risk Factors | 421 | ||
| Pathophysiology | 421 | ||
| Clinical Features | 421 | ||
| Association with Eosinophilia | 421 | ||
| Acute and Chronic Management | 422 | ||
| Inflammatory bowel diseases | 422 | ||
| Epidemiology | 422 | ||
| Risk Factors | 423 | ||
| Pathophysiology | 423 | ||
| Clinical Features | 423 | ||
| Association with Eosinophilia | 423 | ||
| Mucosal eosinophilia | 424 | ||
| Eosinophil products and inflammatory bowel disease | 424 | ||
| Acute and Chronic Management | 424 | ||
| Differential Diagnosis | 425 | ||
| Prognosis | 425 | ||
| Parasitic infections | 425 | ||
| Introduction | 425 | ||
| Hookworm Infection | 426 | ||
| Strongyloidiasis | 426 | ||
| Diagnostic Approach | 428 | ||
| Future considerations and summary | 428 | ||
| References | 428 | ||
| Eosinophilia in Hematologic Disorders | 439 | ||
| Key points | 439 | ||
| Introduction | 439 | ||
| Reactive eosinophilia | 440 | ||
| Reactive eosinophilia of hematologic and oncologic interest | 440 | ||
| Lymphocyte variant hypereosinophilic syndrome | 440 | ||
| Eosinophilic myeloid disorders | 441 | ||
| Epidemiology | 441 | ||
| Classification | 441 | ||
| Diagnostic Workup | 441 | ||
| Treatment | 444 | ||
| Molecularly defined eosinophilia-associated myeloid neoplasms | 444 | ||
| Idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia not otherwise specified | 447 | ||
| Summary | 448 | ||
| References | 448 | ||
| Eosinophilia in Rheumatologic/Vascular Disorders | 453 | ||
| Key points | 453 | ||
| Introduction | 453 | ||
| Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) | 454 | ||
| Epidemiology | 454 | ||
| Risk Factors | 454 | ||
| Pathophysiology | 455 | ||
| Clinical Features and Diagnostic Investigation | 455 | ||
| Differential Diagnosis | 456 | ||
| Management | 457 | ||
| Prognosis | 458 | ||
| Immunoglobulin G4-related disease | 458 | ||
| Epidemiology | 458 | ||
| Risk Factors | 458 | ||
| Pathophysiology | 458 | ||
| Clinical Features and Diagnostic Investigation | 459 | ||
| Differential Diagnosis | 459 | ||
| Management | 459 | ||
| Prognosis | 459 | ||
| Diffuse fasciitis with eosinophilia | 461 | ||
| Epidemiology | 462 | ||
| Risk Factors | 462 | ||
| Pathophysiology | 463 | ||
| Clinical Features and Diagnostic Investigation | 463 | ||
| Differential Diagnosis | 464 | ||
| Management | 464 | ||
| Prognosis | 465 | ||
| Eosinophilia-myalgia syndrome | 465 | ||
| Epidemiology | 465 | ||
| Risk Factors | 465 | ||
| Pathophysiology | 465 | ||
| Clinical Features and Diagnostic Investigation | 466 | ||
| Differential Diagnosis | 466 | ||
| Management | 466 | ||
| Prognosis | 466 | ||
| Eosinophilic myositis | 466 | ||
| Epidemiology | 466 | ||
| Risk Factors | 466 | ||
| Pathophysiology | 466 | ||
| Clinical Features and Diagnostic Investigation | 467 | ||
| Management | 468 | ||
| Differential Diagnosis | 468 | ||
| Prognosis | 468 | ||
| Summary | 468 | ||
| References | 469 | ||
| Eosinophilia in Pulmonary Disorders | 477 | ||
| Key points | 477 | ||
| General considerations | 477 | ||
| Introduction | 477 | ||
| Mechanisms of Eosinophil Migration into the Lung | 478 | ||
| Role of Eosinophils in Lung Disease | 481 | ||
| Clinical features | 481 | ||
| Asthma | 481 | ||
| Allergic Fungal Airway Disease | 482 | ||
| Eosinophilic Pneumonia | 483 | ||
| Eosinophilic Granulomatosis with Polyangiitis (Formerly Churg-Strauss Syndrome) | 484 | ||
| Idiopathic Hypereosinophilic Syndrome | 484 | ||
| Infections | 484 | ||
| Malignancy | 485 | ||
| Diagnostic tests | 485 | ||
| Management | 485 | ||
| Current controversies | 487 | ||
| Future considerations/summary | 488 | ||
| References | 488 | ||
| Eosinophilia in Infectious Diseases | 493 | ||
| Key points | 493 | ||
| Introduction | 493 | ||
| Initial approach | 494 | ||
| Eosinophilia in the short-term traveler | 494 | ||
| Infectious Causes of Eosinophilia and Fevers in the Traveler | 500 | ||
| Eosinophilia with fevers and abdominal and/or pulmonary symptoms in the traveler | 500 | ||
| Acute schistosomiasis (“Katayama fever”) | 500 | ||
| Fascioliasis | 500 | ||
| Opisthorchiasis | 500 | ||
| Clonorchiasis | 500 | ||
| Gnathostomiasis | 501 | ||
| Paragonimiasis | 501 | ||
| Capillariasis | 501 | ||
| Eosinophilia with fevers and myositis in the traveler | 501 | ||
| Trichinellosis | 501 | ||
| Muscular sarcocystosis | 501 | ||
| Eosinophilia with fevers and central nervous system symptoms in the traveler | 501 | ||
| Infectious Causes of Eosinophilia and Gastrointestinal Symptoms (Without Fever) in the Traveler | 503 | ||
| Hookworm infections | 503 | ||
| Strongyloidiasis | 503 | ||
| Cystoisospora belli (formerly Isospora belli) | 503 | ||
| Echinostomiasis | 503 | ||
| Infectious Causes of Eosinophilia and Allergic or Dermatologic/Soft Tissue Symptoms in the Traveler | 503 | ||
| Anisakiasis | 503 | ||
| Ascariasis | 504 | ||
| Cutaneous larva migrans | 504 | ||
| Onchocerciasis | 504 | ||
| Lymphatic filariasis | 504 | ||
| Loiasis | 504 | ||
| Gnathostomiasis | 504 | ||
| Paragonimiasis | 505 | ||
| Eosinophilia in the traveler conclusions | 505 | ||
| Eosinophilia in indigenous populations (immigrant/refugees) and long-term residents | 505 | ||
| Infectious Causes of Eosinophilia and Gastrointestinal Symptoms in the Immigrant | 505 | ||
| Echinococcosis | 505 | ||
| Ascariasis | 505 | ||
| Trichuriasis | 505 | ||
| Strongyloidiasis | 506 | ||
| Opisthorchis and Clonorchis | 506 | ||
| Hymenolepis nana | 506 | ||
| Schistosoma mansoni infection | 506 | ||
| Infectious Causes of Eosinophilia and Pulmonary Symptoms in the Immigrant | 506 | ||
| Paragonimiasis | 506 | ||
| Echinococcal cyst | 506 | ||
| Tropical pulmonary eosinophilia | 507 | ||
| Eosinophilia Associated with Disorders of Immune Deficiency or Immune Dysregulation | 523 | ||
| Key points | 523 | ||
| Introduction | 523 | ||
| Syndromic causes of increased IgE levels and eosinophilia | 524 | ||
| Autosomal Dominant Hyper IgE Syndrome | 524 | ||
| Clinical features, infections, and management | 524 | ||
| Clinical laboratory findings | 527 | ||
| Genetics and pathogenesis | 528 | ||
| Dedicator of Cytokinesis 8 Deficiency | 528 | ||
| Clinical features, infections, and management | 528 | ||
| Clinical laboratory findings | 529 | ||
| Genetics and pathogenesis | 529 | ||
| Phosphoglucomutase 3 Deficiency | 530 | ||
| Clinical features, infections, and management | 530 | ||
| Clinical laboratory findings | 530 | ||
| Genetics and pathogenesis | 530 | ||
| Wiskott-Aldrich Syndrome | 531 | ||
| Clinical features, infections, and management | 531 | ||
| Clinical laboratory findings | 531 | ||
| Genetics and pathogenesis | 531 | ||
| Severe combined immunodeficiency and related disorders associated with eosinophilia | 532 | ||
| Adenosine Deaminase–Severe Combined Immunodeficiency | 532 | ||
| Clinical features, infections, and management | 532 | ||
| Clinical laboratory findings | 532 | ||
| Genetics and pathogenesis | 532 | ||
| Omenn Syndrome | 533 | ||
| Eosinophilia in Dermatologic Disorders | 545 | ||
| Key points | 545 | ||
| Dermatologic disorders with eosinophilia | 545 | ||
| Pathogenic mechanisms mediated by eosinophils | 546 | ||
| Clinical presentations of dermatoses with eosinophilia | 546 | ||
| Eczematous Pattern | 546 | ||
| Atopic dermatitis | 546 | ||
| Contact dermatitis | 547 | ||
| Scabies and cutaneous larva migrans | 547 | ||
| Primary cutaneous T-cell lymphoma | 548 | ||
| Lymphocytic variant of hypereosinophilic syndromes | 548 | ||
| Langerhans cell histiocytosis | 548 | ||
| Maculopapular Exanthema | 549 | ||
| Drug hypersensitivity reactions | 549 | ||
| Drug reaction with eosinophilia and systemic symptoms | 549 | ||
| Urticarial Pattern | 549 | ||
| Urticaria | 549 | ||
| Eosinophilic cellulitis (Wells’ syndrome) | 550 | ||
| Episodic angioedema with eosinophilia (Gleich’s syndrome) | 550 | ||
| Pregnancy-related diseases | 550 | ||
| Cutaneous mastocytosis | 550 | ||
| Blisters and Pustules | 550 | ||
| Bullous pemphigoid | 550 | ||
| Pemphigus group | 551 | ||
| Incontinentia pigmenti | 551 | ||
| Eosinophilic pustular folliculitis | 551 | ||
| Nodular Lesions | 552 | ||
| Prurigo nodularis | 552 | ||
| Granuloma faciale | 552 | ||
| Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) | 552 | ||
| Angiolymphoid hyperplasia with eosinophilia and Kimura’s disease | 552 | ||
| Primary cutaneous CD30+ lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell l ... | 553 | ||
| Cutaneous B-cell lymphomas | 553 | ||
| Hodgkin’s lymphoma | 554 | ||
| Eosinophilic dermatosis of hematologic malignancies | 554 | ||
| Cutaneous features of hypereosinophilic syndromes | 554 | ||
| Fibrosis | 554 | ||
| Eosinophilic fasciitis | 554 | ||
| Localized scleroderma | 554 | ||
| Diagnostic and therapeutic approaches | 554 | ||
| References | 556 | ||
| Management of Hypereosinophilic Syndromes | 561 | ||
| Key points | 561 | ||
| Introduction | 561 | ||
| Assessment for the presence of eosinophil-mediated complications | 562 | ||
| Pathologic Assessment for Hypereosinophilic Syndrome | 562 | ||
| Shortcomings of Pathology in the Evaluation of the Hypereosinophilic Patient | 564 | ||
| Evaluation of Eosinophil-Mediated Damage Using Methods Other than Histology | 564 | ||
| Are There Surrogate or Predictive Markers for Eosinophil-Mediated Damage? | 565 | ||
| Diagnostic evaluation of hypereosinophilia | 565 | ||
| Establishing a Link Between a Given Condition or Disease and Hypereosinophilia | 565 | ||
| Treatment of hypereosinophilic syndromes associated with a known underlying condition | 566 | ||
| Decision on Whether to Treat the Underlying Condition, the Hypereosinophilia, or Both | 566 | ||
| Specific Management of Myeloid Neoplasms | 567 | ||
| Specific management of lymphocytic variant hypereosinophilic syndrome | 570 | ||
| Treatment of symptomatic and unexplained hypereosinophilia | 570 | ||
| Corticosteroid Treatment | 571 | ||
| Corticosteroid-Sparing Agents and Second-Line Treatment | 571 | ||
| Summary and future considerations | 572 | ||
| References | 572 | ||
| Novel Therapies for Eosinophilic Disorders | 577 | ||
| Key points | 577 | ||
| Introduction | 577 | ||
| The eosinophil surface as a target | 578 | ||
| The eosinophil interior as a target | 581 | ||
| Approved therapies that also target eosinophils or eosinophil-related pathways | 581 | ||
| Novel eosinophil-selective therapies being tested in clinical trials | 582 | ||
| Novel therapies that may indirectly affect eosinophils that are being tested in clinical trials | 589 | ||
| Agents Moving Forward | 589 | ||
| Agents Whose Development is Not Currently Moving Forward | 589 | ||
| Future considerations | 590 | ||
| Summary | 591 | ||
| References | 591 |